home / stock / cyccp / cyccp news

CYCCP News and Press, Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock From 05/08/19

Stock Information
Company Name: Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock
Stock Symbol: CYCCP
Market: NASDAQ
Website: cyclacel.com
Menu
CYCCP CYCCP Quote CYCCP Short CYCCP News CYCCP Articles CYCCP Message Board
Get CYCCP Alerts

News, Short Squeeze, Breakout and More Instantly...
CYCCP - Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results

BERKELEY HEIGHTS, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2019 financial results on...
CYCCP - Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

BERKELEY HEIGHTS, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced Phase 1 clinical data from the company's DNA ...

CYCCP - Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

– Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J., March 27, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines...

CYCCP - Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed as the first predictive biomarker of palbociclib efficacy -- BERKELEY HEIGHTS, N.J., March 25, 2019 ...
CYCCP - Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results

BERKELEY HEIGHTS, N.J., March 20, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2018 fin...

CYCCP - Cyclacel to Participate in 31st Annual ROTH Conference March 18-19

BERKELEY HEIGHTS, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it will participate in the 31 st Annual...

CYCCP - Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019

BERKELEY HEIGHTS, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract highlighting clinical data f...
CYCCP - Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the...

Previous 10 Next 10